e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Diffuse parenchymal lung disease III
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom
W. Jamal, C. Wottons, G. Mirani, N. Foley (Bath, United Kingdom; Wynnewood, United States Of America)
Source:
Annual Congress 2013 –Diffuse parenchymal lung disease III
Session:
Diffuse parenchymal lung disease III
Session type:
Thematic Poster Session
Number:
3819
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Jamal, C. Wottons, G. Mirani, N. Foley (Bath, United Kingdom; Wynnewood, United States Of America). Median survival in unselected patients with idiopathic pulmonary fibrosis in the United Kingdom. Eur Respir J 2013; 42: Suppl. 57, 3819
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Course of disease and cause of death in patients with idiopathic pulmonary fibrosis in Eastern Finland
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014
Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Clinical characteristics of patients with Idiopathic pulmonary fibrosis in a tertiary care center of a developing country
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study
Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology
Year: 2013
Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016
Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years
Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions
Year: 2013
Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment
Source: International Congress 2014 – ILDs 5
Year: 2014
Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013
Variation in mortality from interstitial lung disease by diagnosis
Source: International Congress 2015 – IIPs: orphan
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept